Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration

Anders Fredriksson1, Trevor Archer, Henrik Alm

  • 1Department of Neuroscience, Psychiatry Ulleråker, Uppsala University, SE-750 17 Uppsala, Sweden. anders.fredriksson@neuro.uu.se

Insights

Neonatal exposure to ketamine and diazepam causes brain cell degeneration and long-term deficits in motor activity and learning. This highlights risks associated with these drugs in pediatric anesthesia.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pharmacology

Background:

  • Early postnatal brain development is sensitive to pharmacological agents.
  • Ketamine (glutamate NMDA receptor antagonist) and diazepam (GABA(A) receptor agonist) are used in anesthesia.

Purpose of the Study:

  • To investigate the effects of neonatal ketamine and diazepam exposure on brain development and function.
  • To assess neuronal cell degeneration and subsequent behavioral deficits.

Main Methods:

  • Neonatal NMRI male mice were administered ketamine, diazepam, co-administered ketamine and diazepam, or vehicle on postnatal day 10.
  • Neuronal cell degeneration was analyzed on postnatal day 11 using Fluoro-Jade staining.
  • Motor activity and learning performance were assessed at 2 months of age.

Main Results:

  • Ketamine induced parietal cortex degeneration; diazepam caused laterodorsal thalamus degeneration.
  • Combined ketamine and diazepam exposure resulted in the most severe parietal cortex cell degeneration.
  • Ketamine and ketamine + diazepam treated mice showed significant deficits in motor activity, learning, and memory.

Conclusions:

  • Neonatal exposure to ketamine and diazepam can lead to significant neuronal cell degeneration and lasting functional deficits.
  • The findings suggest potential risks of ketamine and diazepam for neonatal brain development and function.
  • These results have implications for the choice of anesthetic agents in neonatal care.

Related Concept Videos